ALBERTA PRECISION LABORATORIES
Leaders in Laboratory Medicine

Laboratory Bulletin

DATE:	2021 September 6
TO:	All clinicians in North Sector
FROM:	Molecular Pathology North
RE:	CALR and MPL transition to NGS

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- CALR and MPL mutational analysis is moving from single gene testing to next-generation sequencing (NGS). Beginning August 20, 2021, all cases for whom CALR and/or MPL testing is required will be tested on the myeloid DNA panel using NGS.

Background

- CALR and MPL mutations are seen in approximately 45% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF). Currently, these tests are offered sequentially in the evaluation of patients with elevated platelets or myelofibrosis. Many patients tested for these mutations will eventually need additional testing via NGS for risk stratification. In order to decrease turnaround times and provide more comprehensive data for our patients, Molecular Pathology Lab North has decided to transition the CALR and MPL tests to our myeloid NGS panel.

How this will impact you

- If you need testing for CALR and/or MPL, the molecular pathology laboratory will order Myeloid Molecular Analysis. The patient result will include information on CALR and MPL as well as other genes on the panel.

Action Required

- Access CALR and/or MPL results from the Myeloid Molecular Analysis report in EPIC/NetCare.

Effective: August 20, 2021

Questions/Concerns

- Dr. Cheryl Mather, Medical Lead, Molecular Pathology North
  Cheryl.Mather@APLabs.ca; 780-407-2717

Approved by

- Dr. Imran Mirza, Provincial Medical Lead, Molecular Pathology Program